Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 Third Quarter
Filed with TSE · · 10 pages · English
Summary by 6ix AI
This document serves as a supplement to the Kessan Tanshin disclosed at the Tokyo Stock Exchange on the same date. It includes consolidated financial results, revenue by regional control function, and the status of main products, among other details. The appendix also outlines the company's R&D pipeline and provides insights into revenue trends and cash flows.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Kyowa Kirin
- Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome
- Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
- Kyowa Kirin Announces Agreement with U.S. Administration to Reduce Treatment Costs for Americans
- Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2026 Semi Annual
- European Commission Approves Crysvita® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union
Follow Kyowa Kirin into a list and get an email when it puts out news.
Follow Kyowa Kirin